ライフサイエンスコーパス: myectomy

1 ) after pacing (p = 0.02 for comparison with myectomy).

2 nts, all of whom had MV surgery (with septal myectomy).

3 dapt the repair, often employing an extended myectomy.

4 25 were treated by PTSMA and 26 patients via myectomy.

5 septal myocardial ablation (PTSMA) or septal myectomy.

6 at one year are similar to those of surgical myectomy.

7 uctive hypertrophic cardiomyopathy following myectomy.

8 s who are most likely to benefit from septal myectomy.

9 he 45 patients who underwent isolated septal myectomy.

10 predictive of clinical outcome after septal myectomy.

11 bstructive cardiomyopathy who undergo septal myectomy.

12 operative planning for interventions such as myectomy.

13 l septal ablation and 1377 (75%) with septal myectomy.

14 cal results are comparable to that of septal myectomy.

15 urgeons with instructive guidance for septal myectomy.

16 and post-operative outcomes following septal myectomy.

17 nspecting their heart samples extracted from myectomy.

18 a clinical diagnosis of HCM underwent septal myectomy.

19 e, in this area, ASA still seems inferior to myectomy.

20 of patients with HCM who underwent surgical myectomy.

21 otion of the MV is relieved through adequate myectomy.

22 HOCM) undergoing extended transaortic septal myectomy.

23 and septal thickness that underwent isolated myectomy.

24 ected patients, and when needed, by surgical myectomy.

25 a Siemens 1.5 T scanner, followed by septal myectomy.

26 nd 0.6% had complete heart block (CHB) after myectomy.

27 procedural complication rate exceeds that of myectomy.

28 s of age have better symptom resolution with myectomy.

29 ears, 17 women) subsequently needed surgical myectomy.

30 illator placement, 5 valve surgery, 2 septal myectomy, 1 aortic arch replacement, 1 myocardial bridge

31 tion for symptoms; 2 (4%) underwent a septal myectomy; 14 (25%) received an implantable cardioverter-

32 ession of HCM, with all 5 requiring surgical myectomy, 3 of the 5 having a family history of sudden c

33 e 117 patients who underwent surgical septal myectomy, 47 (40%) developed left bundle branch block.

34 , p = 0.0009), and more frequently underwent myectomy (60% vs. 38%, p = 0.002).

35 hed patients who underwent isolated surgical myectomy (8-year survival estimate, 79% versus 79%; P=0.

36 At myectomy, a long muscular discontinuity displaced the an

37 s judged unsuitable for conventional myotomy/myectomy, a novel surgical strategy was designed to remo

38 jacent right bundle tissue, whereas surgical myectomy affects the endocardial portion of the basal an

39 We sought to determine the outcome of myectomy after unsuccessful alcohol ablation.

40 non-pharmacologic intervention with surgical myectomy, alcohol ablation, or pacing; outflow gradient

41 101 consecutive patients with HCM undergoing myectomy and 9 normal controls.

42 eptal reduction therapies including surgical myectomy and alcohol septal ablation are limited by surg

43 Septal myectomy and alcohol septal ablation for severely sympto

44 Surgical septal myectomy and alcohol septal ablation relieve left ventri

45 phologic differences that result from septal myectomy and alcohol septal ablation using cardiac magne

46 rily centered on the choice between surgical myectomy and alcohol septal ablation.

47 Surgical myectomy and dual-chamber pacing improve subjective meas

48 vere obstructive symptoms requiring surgical myectomy and implantation of an implantable cardioverter

49 Both myectomy and PTSMA reduce LVOT obstruction and significa

50 This review discusses the indications for myectomy and surgical technique for treating benign esse

51 yped HCM patients (n=97) undergoing surgical myectomy and tissue from 23 controls.

52 t and protein levels were analyzed in septal myectomy and transplant specimens from 46 genotyped HCM

53 ted more inferiorly in the basal septum than myectomy and usually extending into the right ventricula

54 ents had surgical relief of obstruction (91% myectomy) and 6 (2%) alcohol septal ablation.

55 Twenty patients underwent surgical myectomy, and 19 received dual-chamber pacemakers based

56 herapeutic hypothermia, advances in surgical myectomy, and alcohol ablation.

57 m 76+/-57 to 9+/-17 mm Hg (p = 0.0001) after myectomy, and from 77+/-61 to 55+/-39 mm Hg (p = 0.07) a

58 s, including septal alcohol ablation, septal myectomy, and implantable cardioverter defibrillators, a

59 de noninvasive modalities, chemodenervation, myectomy, and selective neurectomy.

60 ulation, and to patients undergoing surgical myectomy, as well, without an increased risk of sudden c

61 er-matched patients who had undergone septal myectomy at Mayo Clinic (P<0.0001).

62 utaneous alcohol septal ablation or surgical myectomy at Mayo Clinic between 1999 and 2003 were revie

63 PTSMA, 62 +/- 43 mm Hg vs. 7 +/- 7 mm Hg for myectomy, both p < 0.0001).

64 7 for PTSMA, 3.3 +/- 0.5 vs. 1.5 +/- 0.7 for myectomy, both p < 0.0001).

65 on and 2.4 +/- 0.6 cm vs. 1.7 +/- 0.2 cm for myectomy, both p < 0.001).

66 ranch block is a common sequela after septal myectomy but does not influence post-operative mortality

67 Myectomy can be successfully performed after failed alco

68 performed as an adjunctive procedure during myectomy can reduce symptomatic AF episodes (70% of pati

69 .6+/-2.8 to 8.7+/-3.0 min (p = 0.0003) after myectomy compared with a change from 6.4+/-2.1 to 7.0+/-

70 flow tract gradient, and higher frequency of myectomy compared with participants with normal test res

71 rdiomyocytes from 26 HCM patients undergoing myectomy compared with those from nonfailing nonhypertro

72 ents, additional procedures on MV and PM (+/-myectomy) could be considered.

73 ereas rates of atrial fibrillation and prior myectomy did not differ significantly between groups.

74 Additional myectomy did not reduce the risk for reoperation (P=0.92

75 Myectomy does not show additional advantages, and becaus

76 There are four reasons to consider myectomy for patients with BEB.

77 icular samples from 4 patients who underwent myectomy for refractory outflow obstruction, compared wi

78 nary ethanol with standard therapy (surgical myectomy) for the treatment of hypertrophic obstructive

79 diomyopathy who underwent transaortic septal myectomy from 1961 to 2016 were analyzed.

80 cardiomyopathy who underwent isolated septal myectomy from 1986 to 1992 were analyzed.

81 athy referred for alcohol septal ablation or myectomy from 1998 to 2006, 138 patients (median age, 64

82 ts with obstructive HCM who underwent septal myectomy from 2000 to 2016.

83 e resting PG remained lower in the PTSMA and myectomy groups (24 +/- 19 mm Hg and 11 +/- 6 mm Hg, res

84 al leaflet and aortic valve was inspected at myectomy in 106 consecutive patients with HCM.

85 operative mortality rate for isolated septal myectomy in most centers is <1%.

86 ock are recognized sequelae following septal myectomy in patients with hypertrophic cardiomyopathy, b

87 lly effective compared to internal sphincter myectomy in short-term follow-up.

88 o establish the risks and benefits of septal myectomy in the modern surgical era.

89 d with HCM and severe basal LVOTO undergoing myectomy in whom the diagnosis of AFC was suspected by t

90 lique weakening procedures; Inferior Oblique Myectomy (IOM), Inferior Oblique combined Resection-Ante

91 ators working in high-volume centers, septal myectomy is highly effective with a >90% relief of obstr

92 the route of the septal perforators, whereas myectomy is not.

93 Long-term survival after myectomy is similar to that of the general population an

94 Procedural morbidity and mortality risk with myectomy is similar to, and in some institutions less th

95 Although septal myectomy is the preferred treatment for medication-refra

96 Although surgical myectomy is the primary treatment for amelioration of ou

97 ft ventricular outflow obstruction, surgical myectomy may be indicated, with little current role for

98 Therefore, isolated myectomy may not relieve outflow obstruction and symptom

99 Both dual-chamber pacing and surgical myectomy may result in subjective symptom improvement.

100 y in 3; mitral valve repair in 2; and septal myectomy, mitral valve replacement, aortoplasty, subaort

101 After surgical myectomy, more patients were on medications (p < 0.05) a

102 Ventricular septal myotomy/myectomy (Morrow procedure) is the standard surgical opt

103 ckening were negatively associated with post-myectomy mortality.

104 in end-stage failing heart, and 76 +/- 6% in myectomy muscle samples (donor versus myectomy p < 0.05)

105 In 2016 we identified, at myectomy, muscular mitral-aortic discontinuity in 5 youn

106 ined in HCM patients before and after septal myectomy (n = 24) and alcohol septal ablation (n = 24).

107 nts evaluated from 1983 to 2001: 1) surgical myectomy (n = 289); 2) LV outflow obstruction without op

108 ion (n=49) or the Maze procedure at surgical myectomy (n=72).

109 mm, bilateral inferior oblique recession or myectomy) occurred in 11 cases.

110 In this nonrandomized study, myectomy offered greater reduction in left ventricular o

111 y sought to determine the impact of surgical myectomy on long-term survival in hypertrophic cardiomyo

112 apamil, disopyramide) and the septal myotomy-myectomy operation, which is the standard of care for se

113 A total of 2,107 septal myectomy operations performed in adults from January 199

114 Septal reduction therapy (SRT), surgical myectomy or alcohol ablation, is recommended for obstruc

115 cular obstruction, septal reduction therapy (myectomy or alcohol septal ablation) is recommended.

116 al reduction therapy, either surgical septal myectomy or alcohol septal ablation.

117 be considered before proceeding to surgical myectomy or alternate strategies.

118 rwent TAR and highest in those who underwent myectomy or anterior extirpation.

119 -up of 327 days (90-743 days) after surgical myectomy (or alcohol septal ablation), 92% and 95% of pa

120 abolition of subaortic gradients by surgical myectomy (or percutaneous alcohol septal ablation) resul

121 nsplantation for end-stage failure, surgical myectomy (or selectively, alcohol septal ablation) to al

122 to prevent sudden death, drugs and surgical myectomy (or, alternatively, alcohol septal ablation) fo

123 agnosis, degree of hypertrophy, incidence of myectomy, or family history of HCM or sudden death.

124 ardiac death stratification, surgical septal myectomy, or for implantable cardioverter-defibrillators

125 6% in myectomy muscle samples (donor versus myectomy p < 0.05).

126 rom 19.4+/-6.4 to 22.2+/-6.5 ml/kg/min after myectomy (p = 0.004), whereas the pacing group did not e

127 nd gender-matched patients who had undergone myectomy (P=0.18).

128 frequency in patients with or without prior myectomy (P=0.84).

129 Myectomy patients <or=65 years of age had significantly

130 mpared with age- and gradient-matched septal myectomy patients at the Mayo Clinic.

131 red to nonoperated obstructive HCM patients, myectomy patients experienced superior survival free fro

132 Ninety percent of myectomy patients experienced symptomatic improvement as

133 ndle branch block developed in 46% of septal myectomy patients, and right bundle branch block was evi

134 Surgical myectomy performed to relieve outflow obstruction and se

135 Surgical septal myectomy permanently abolishes systolic anterior motion

136 Septal myectomy provides consistent resection of the obstructin

137 Surgical myectomy provides excellent relief of symptoms in most p

138 fit and restoration of quality of life, with myectomy providing a long-term survival similar to that

139 Septal myectomy reduces or eliminates left ventricular outflow

140 Myectomy-related CHB is rare in patients with baseline n

141 Myectomy remains essential for treating blepharospasm pa

142 Surgical myectomy resulted in a significantly higher incidence of

143 proteomics, metabolomics, and lipidomics on myectomy samples (genotype-positive N=19; genotype-negat

144 HCM myectomy samples exhibited (1) increased glucose and gly

145 donor hearts, explanted failing hearts, and myectomy samples from patients with HCM.

146 ecious human cardiac samples, that is, small myectomy samples, to address the alteration of contracti

147 In this retrospective study, septal myectomy seems to reduce mortality risk in severely symp

148 tive surgical strategies to standard myotomy/myectomy, similar to those described here.

149 Previous data on septal myectomy (SM) and alcohol septal ablation (ASA) in obstr

150 outcomes of septal ablation (SA) with septal myectomy (SM) for treatment of hypertrophic obstructive

151 ies aged >65 years who underwent SRT, septal myectomy (SM) or alcohol septal ablation (ASA), from 201

152 ol septal ablation (ASA) and surgical septal myectomy (SM) with patient management in accordance with

153 ingle nuclei RNA-sequencing was performed on myectomy specimens from HCM patients with left ventricul

154 nges in myocardial efficiency and effects of myectomy surgery.

155 ere independently associated with worse post-myectomy survival.

156 -II protein levels were higher in HCM septal myectomies than in nonfailing control hearts and in 60-w

157 After isolated septal myectomy, the percentage of patients with MR grade >/=3

158 At time of surgical myectomy, the ventricular proteome, independent of genot

159 With septal myectomy, there was a discrete area of resected tissue c

160 blished disease stage (mouse-HCM), and human myectomy tissue (human-HCM).

161 Respirometry was performed on septal myectomy tissue from patients with HCM (n = 59) to evalu

162 Here, myectomy tissue from patients with obstructive hypertrop

163 te-control hearts at 24 weeks of age, and in myectomy tissue of patients with obstructive HCM/control

164 alleles of FHOD3-V1151I were detected in HCM myectomy tissue.

165 haracterize sarcomeric proteoforms in septal myectomy tissues from HCM patients exhibiting severe out

166 Multivariate analysis showed myectomy to have a strong, independent association with

167 e the outflow gradient in which an extensive myectomy trough (wider at its apical than basal extent)

168 , 1-, 5-, and 10-year overall survival after myectomy was 98%, 96%, and 83%, respectively, and did no

169 Myectomy was performed at 19 +/- 15 months after ablatio

170 ed pre-operatively; in 1,830 (96.1%), septal myectomy was performed without a direct MV procedure.

171 , mortality in those with paced rhythm after myectomy was significantly increased relative to those w

172 Solitary inferior oblique myectomy, was the most common surgery in both unilateral

173 omyopathy (HCM) patients undergoing surgical myectomy, we sought to determine the association between

174 myocardium of HCM patients undergoing septal myectomy were remarkably consistent, regardless of the u

175 judged as not optimal candidates for septal myectomy, were referred for management of severe, drug-r

176 s to compare the treatment effects of septal myectomy with dual-chamber pacing in patients with hyper

177 lly reviewing all studies comparing ASA with myectomy with long-term follow-up, (aborted) sudden card

178 recessions, tenotomy and reattachment (TAR), myectomy with or without pulley fixation, and anterior e

179 ort study assesses the association of septal myectomy with quality of life in patients with left vent

180 den death; low risk to high benefit surgical myectomy (with percutaneous alcohol ablation a selective